

|         | AVASTIN | LUCENTIS | EYLEA | Brolucizumab |
|---------|---------|----------|-------|--------------|
| Q3 2011 | 63%     | 37%      | 0%    |              |
| Q1 2012 | 57%     | 32%      | 11%   |              |
| Q2      | 58%     | 28%      | 14%   |              |
| Q3      | 53%     | 27%      | 20%   |              |
| Q4      | 48%     | 30%      | 21%   |              |
| Q1 2013 | 48%     | 29%      | 23%   |              |
| Q2      | 49%     | 28%      | 23%   |              |
| Q3      | 47%     | 27%      | 26%   |              |
| Q4      | 51%     | 28%      | 21%   |              |
| Q1 2014 | 50%     | 25%      | 24%   |              |
| Q2      | 50%     | 29%      | 21%   |              |
| Q3      | 48%     | 27%      | 25%   |              |
| Q4      | 45%     | 27%      | 28%   |              |
| Q1 2015 | 46%     | 22%      | 32%   |              |
| Q2      | 43%     | 25%      | 32%   |              |
| Q3      | 41%     | 24%      | 35%   |              |
| Q4      | 44%     | 21%      | 35%   |              |
| Q1 2016 | 45%     | 18%      | 36%   |              |
| Q2      | 44%     | 19%      | 37%   |              |
| Q3      | 45%     | 19%      | 36%   |              |
| Q4      | 43%     | 20%      | 37%   |              |
| Q1 2017 | 44%     | 19%      | 37%   |              |
| Q2      | 44%     | 17%      | 39%   |              |
| Q3      | 44%     | 18%      | 38%   |              |
| Q4*     | 45%     | 18%      | 37%   |              |
| Q1 2018 | 44%     | 20%      | 37%   |              |
| Q2      | 42%     | 19%      | 39%   |              |
| Q3      | 43%     | 20%      | 37%   |              |
| Q4      | 42%     | 20%      | 38%   |              |
| Q1 2019 | 41%     | 20%      | 39%   |              |
| Q2      | 42%     | 20%      | 38%   |              |
| Q3      | 40%     | 19%      | 41%   |              |
| Q4      | 44%     | 15%      | 39%   | 2%           |
| Q1 2020 | 42%     | 15%      | 39%   | 4%           |
| Q2      | 39%     | 18%      | 39%   | 4%           |
| Q3      | 42%     | 14%      | 39%   | 5%           |
| Q4      | 40%     | 15%      | 40%   | 5%           |
| Q2 2021 | 39%     | 15%      | 42%   | 4%           |

Samsung v. Regeneron  
IPR2023-00442  
U.S. Pat. 10,130,681  
Exhibit 2279